MedPath

Epidural Oxycodone for Pain Management for Lower Limb Amputation

Not Applicable
Recruiting
Conditions
Oxycodone
Pain
Epidural
Lower Limb Amputation
Interventions
Registration Number
NCT06276179
Lead Sponsor
Kafrelsheikh University
Brief Summary

The aim of this study is to evaluate the effect of epidural oxycodone for pain management after lower limb amputation.

Detailed Description

Phantom limb pain (PLP) is often described as tingling, throbbing, sharp, pins/needles in the limb that is no longer there. It occurs more commonly in upper extremity amputations than lower extremities and tends to be intermittent in frequency. Pain severity varies, and onset can be immediate or years afterward.

The preventive strategies for the PLP pain are difficult to manage and if not addressed adequately may lead to chronic pain. The perioperative role of the anesthesiologist and the acute pain physician is important in the management of somatic and sometimes neuropathic postoperative pain.

Oxycodone is a semi-synthetic narcotic analgesic and historically has been a popular drug of abuse among the narcotic abusing population. Oxycodone is used orally or intravenously.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Age 18 to 65 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status II or III.
  • Undergoing lower limb amputation.
  • Under epidural anesthesia.
Exclusion Criteria
  • Hypersensitivity to opioids.
  • Cardiac arrhythmias.
  • Acute asthma or other obstructive airways disease.
  • Severe renal impairment.
  • Pregnancy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Oxycodone (study group)OxycodonePatient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.
Bupivacaine (control group)BupivacainePatient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
Primary Outcome Measures
NameTimeMethod
Acute postoperative pain scores48 hours postoperatively

Acute postoperative pain scores will be assessed using numerical rating scale (NRS).Each patient will be instructed about postoperative pain assessment with NRS. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at PACU, 2, 4, 6, 12, 24, 36 and 48 h postoperatively.

Secondary Outcome Measures
NameTimeMethod
Time to the first request for the rescue analgesia48 hours postoperatively

Time to the first request for the rescue analgesia (time from end of surgery to first dose of morphine administrated). If numerical rating scale (NRS) is more than 3, intravenous morphine 3mg will be administered as rescue analgesia.

Postoperative morphine consumption48 hours postoperatively

Acute postoperative pain scores will be assessed using numerical rating scale (NRS).

NRS will be assessed at PACU, 2, 4, 6, 12, 24, 36 and 48 h postoperatively. A standardized analgesic regimen will be prescribed in the post-operative period. All patients will receive paracetamol 1 gm every 6 h as routine analgesia. If NRS is more than 3, intravenous morphine 3mg will be administered as rescue analgesia.

Incidence of phantom limb pain3 months postoperatively

Incidence of phantom limb pain will be assessed 3 months after surgery

Adverse effects48 hours postoperatively

Adverse effects such as postoperative nausea and vomiting, pruritus, urinary retention, constipation, and respiratory depression will be recorded.

Trial Locations

Locations (1)

Kafrelsheikh University

🇪🇬

Kafr Ash Shaykh, Kafrelsheikh, Egypt

© Copyright 2025. All Rights Reserved by MedPath